Among the top six compounds, compound C03 with minimal IC50 of 9.97μM in K562 cells (myeloid leukemia), downregulates the expression of endogenous PDXK in a dose-dependent manner in K562 leukemic cells. This evidence concerns the gene PDXK and myeloid leukemia.